Single centre experience of efficacy and toxicity of reduced-dose melphalan conditioning (140 mg/m2 or 110 mg/m2) in autologous stem cell transplantation for multiple myeloma

被引：0
|
作者：
Troy-Barnes, E. [1 ]
Melotti, D. [1 ]
Camilleri, M. [1 ]
Horder, J. [1 ]
Newrick, F. [1 ]
Marfil, J. [1 ]
Lee, L. [2 ]
Mahmood, A. S.
Wisniowski, B.
Papanikolaou, X. [1 ]
Wechalekar, A. [3 ]
Sive, J. [1 ]
Popat, R. [4 ]
Yong, K. [2 ]
Rabin, N. [1 ]
Kyriakou, C. [1 ]
机构：
[1] Univ Coll London Hosp NHS Fdn Trust, London, England
[2] UCL, Inst Canc, London, England
[3] UCL, Ctr Amyloidosis & Acute Phase Prot, London, England
[4] Univ Coll London Hosp, Clin Res Facil, Natl Inst Hlth Res, London, England
来源：
BONE MARROW TRANSPLANTATION | 2022年 / 57卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P146
引用
收藏
页码：178 / 179
页数：2
相关论文
共 50 条
  • [31] Evaluation of different intermediate melphalan doses (80 mg/m2 vs 100 mg/m2 vs 120 mg/m2) in multiple myeloma patients.
    Palumbo, A
    Triolo, S
    Argentino, C
    Bringhen, S
    Dominietto, A
    Giaccone, L
    Rus, C
    Omedè, P
    Pileri, A
    Boccadoro, M
    BLOOD, 1999, 94 (10) : 578A - 578A
  • [32] AUTOLOGOUS TRANSPLANTATION OF HEMATOPOYETIC PROGENITORS IN PATIENTS WITH MULTIPLE MYELOMA DURING HEMODIALYSIS WITH MELFALAN 140MG/M2 CONDITIONING. EXPERIENCE OF A CENTER
    Arnao Maria, Moya
    Perianes Valentin, Cabanas
    Salinas Andres, Sanchez
    Blanquer Miguel, Blanquer
    Marin Amelia, Martinez
    Poveda Elena, Fernandez
    Mitat Alina, Ramon
    Piqueras Mercedes, Berenguer
    Maria Jose, Moreno Belmonte
    Col Jorge, Monserrat
    Ana Maria, Garcia Hernandez
    Lopez Raul, Perez
    Fierez Eduardo, Salido
    Candel Faustino, Garcia
    Amor Antonia, Melero
    Espuch Joaquin, Gomez
    Francesca, Labbadia
    Juan Jose, Cerezo Machado
    Ana Belen, Martinez Garcia
    Jose Maria, Moraleda Jimenez
    HAEMATOLOGICA, 2016, 101 : 117 - 117
  • [33] Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma
    P Moreau
    N Milpied
    B Mahé
    N Juge-Morineau
    M-J Rapp
    R Bataille
    J-L Harousseau
    Bone Marrow Transplantation, 1999, 23 : 1003 - 1006
  • [34] Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma
    Moreau, P
    Milpied, N
    Mahé, B
    Juge-Morineau, N
    Rapp, MJ
    Bataille, R
    Harousseau, JL
    BONE MARROW TRANSPLANTATION, 1999, 23 (10) : 1003 - 1006
  • [35] 200 mg/m2 melphalan-the gold standard for multiple myeloma
    Giralt, Sergio
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (09) : 490 - 491
  • [36] Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
    Auner, Holger W.
    Iacobelli, Simona
    Sbianchi, Giulia
    Knol-Bout, Cora
    Blaise, Didier
    Russell, Nigel H.
    Apperley, Jane F.
    Pohlreich, David
    Browne, Paul V.
    Kobbe, Guido
    Isaksson, Cecilia
    Lenhoff, Stig
    Scheid, Christof
    Touzeau, Cyrille
    Jantunen, Esa
    Anagnostopoulos, Achilles
    Yakoub-Agha, Ibrahim
    Tanase, Alina
    Schaap, Nicolaas
    Wiktor-Jedrzejczak, Wieslaw
    Krejci, Marta
    Schoenland, Stefan O.
    Morris, Curly
    Garderet, Laurent
    Kroeger, Nicolaus
    HAEMATOLOGICA, 2018, 103 (03) : 514 - 521
  • [37] Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients
    Brioli, Annamaria
    vom Hofe, Felix
    Rucci, Paola
    Ernst, Thomas
    Yomade, Olaposi
    Hilgendorf, Inken
    Scholl, Sebastian
    Sayer, Herbert
    Muegge, Lars-Olof
    Hochhaus, Andreas
    von Lilienfeld-Toal, Marie
    BONE MARROW TRANSPLANTATION, 2021, 56 (05) : 1209 - 1212
  • [38] Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients
    Annamaria Brioli
    Felix vom Hofe
    Paola Rucci
    Thomas Ernst
    Olaposi Yomade
    Inken Hilgendorf
    Sebastian Scholl
    Herbert Sayer
    Lars-Olof Mügge
    Andreas Hochhaus
    Marie von Lilienfeld-Toal
    Bone Marrow Transplantation, 2021, 56 : 1209 - 1212
  • [39] A Lower Dose of Melphalan (140 mg/m2) As Preparative Regimen for Multiple Myeloma in Patients >65 or with Renal Dysfunction
    Saunders, Ila Maewal
    Gulbis, Alison
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S293 - S294
  • [40] A Lower Dose Of Melphalan (140 mg/m2) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction
    Saunders, Ila Maewal
    Gulbis, Alison M.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD, 2013, 122 (21)
12345